102 related articles for article (PubMed ID: 9205758)
1. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
Farré M; Roset PN; Badenas JM; Ugena B; Márquez M; Albet C; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
Albet C; Pérez JA; Rozman E; Márquez M; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ebrotidine in rats and dogs.
Albet C; Pérez JA; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
[TBL] [Abstract][Full Text] [Related]
5. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
6. Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
Muñoz-Navas M; Honorato J; Reina-Ariño M; Márquez M; Herrero E; Villamayor F; Torres J; Roset PN; Fíllat O; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):539-44. PubMed ID: 9205761
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
Romero A; Gómez F; Villamayor F; Ballesta A; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):524-7. PubMed ID: 9205757
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
Gabryelewicz A; Czajkowski A; Skrodzka D; Marlicz K; Luca de Tena F; Aldeguer M; Chantar C; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
[TBL] [Abstract][Full Text] [Related]
9. Acute toxicity studies of ebrotidine.
Grau MT; Romero A; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):490-1. PubMed ID: 9205750
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
Puscas I; Puscas C; Coltau M; Pasca R; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):568-72. PubMed ID: 9205767
[TBL] [Abstract][Full Text] [Related]
11. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[TBL] [Abstract][Full Text] [Related]
12. Carcinogenicity studies on ebrotidine.
Romero A; Rives A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):515-9. PubMed ID: 9205755
[TBL] [Abstract][Full Text] [Related]
13. Subacute toxicity of ebrotidine in rats and dogs.
Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):492-7. PubMed ID: 9205751
[TBL] [Abstract][Full Text] [Related]
14. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
15. Chronic toxicity of ebrotidine in rats and dogs.
Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):498-504. PubMed ID: 9205752
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
[TBL] [Abstract][Full Text] [Related]
17. Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer. A multicentre, double-blind, parallel, randomized, controlled study.
Tulassay Z; Döbrönte Z; Farkas I; Juhász L; Simon L; Prónai L; Torres J; Márquez M
Arzneimittelforschung; 1997 Apr; 47(4A):551-5. PubMed ID: 9205763
[TBL] [Abstract][Full Text] [Related]
18. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
Gedliczka O; Bobrzynski A; Rembiasz K; Fillat O; Torres J; Herrero E; Márquez M; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):560-4. PubMed ID: 9205765
[TBL] [Abstract][Full Text] [Related]
20. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan MY; Stambuk D
Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]